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Acid-base balance. See also pH
acidosis, fractional excretion of anions (abst) 706
alkalosis, Ca2, Mg2 reabsorption (abst) 1789
Acid-base transport, chronic hyperfiltration (abst) 1790
Acidosis
hypoxia-induced protease, PT (abst) 1768
metabolic, fractional excretion of anions (abst) 706
Acitretin, skin complications post-transplant (abst) 1396
Acute bone edema, post-transplant (abst) 1419
Acute pancreatitis and ARF (abst) 703
Acute renal failure (ARF)
acute pancreatitis (abst) 703
APACHE III score, clinical analysis (abst) . . . 702
causes (abst) 703
CD8 leukocyte depletion (abst) 333
children, prognostic factors (abst) 694
children (abst) 694
clinical characteristics in NS (abst) 702
clinical course and dialysis (abst) 703
clinical course and mortality (abst) 703
clinical study (abst) 702
elderly (abst) 693
epidemiology, community-based study 811
nonoliguric ischemia, glucose reabsorption (abst) 702
post-cardiac surgery (abst) 1402
post-ischemic, EPO production 1958
renal biopsy in (abst) 704
"renal-dose" dopamine 4
survival, intermittent vs. continuous (abst) 1770
yersinia pseudotuberculosis (abst) 702
Acute tubular necrosis (ATN)
developmental Pax-2 and WTI expressed (abst) 1781
IGF-l variant (abst) 1405
myoglobin inhibits HK-2 proliferation 796
Acyclovir
CMV prophylaxis, high-risk transplantation 57:S-62
nucleoside-analogs, volume-activated Cl channels
(abst) 1788
Adenosine, natriuresis, renal nerve involvement (abst) . . . 1818
Adenovirus vector, VEGF induces angiogenesis (abst)... 1804
Adhesion molecules. See also Intercellular adhesion
molecule-i (ICAM-1)
1,25(OH)2D3 synthetic analog, PT cells (abst) 1431
blood monocytes, peritoneal rnacrophages, CAPD
(abst) 1393
endothelial cells, anti-DNA autoantibodies (abst) 1393
steroid pulse therapy, membranous nephropathy (abst). 1786
Adrenomedullin expression, afferent arterioles, renin
(abst) 1810
Advanced glycation end products (AGEs)
DN, aminoguanidine in 627
DN, pathogenesis (abst) 1415
transcriptional control in MC 1166
Afferent arterioles
adrenomedullin expression, renin (abst) 1810
Cl channel and vasoconstriction 864
Cl depletion blocks response to high K (abst) 1785
Na-Ca exchange in renal arterioles 1856, 1889
permeability differences, rat kidneys (abst) 1797
Age. See Children; Elderly
Alanine
glucose formation, cortex tubules (abst) 1793
glyoxylate aminotransferase defect, hyperoxaluria 1747
Albumin
endocytosis of, GTP-BP mediates receptor (abst) 1799
endocytosis of, megalin as receptor for (abst) 1799
loss, reduced convective, hemofiltration or HDF 432
measuring permeability, method for 1352
serum, and urea clearance in CPD 243
Albuminuria
ACEi therapy, long-term renal outcome (abst) 1768
arterial BP, DN, circadian rhythm 579
mAb, aminopeptidase A epitopes (abst) 331
microalbuminuria, intracellular Ca in NIDDM 618
microalbuminuria, total renin in IDDM 902
oxidant injury, minimal change disease (abst) 332
tubulointerstitial response, integrins 1310
Aldose reductase pathway
mRNA and K depletion 828
pathogenesis of diabetic nephropathy (abst) 1404
Aldosterone
AVP, Na transport in rat CCD 57:S-35
epithelial Na channel in A6 kidney cells (abst) 1783
Na/H exchange, rat CCD (abst) 1789
regulates mRNAs in A6 kidney cells (abst) 1784
Aldosteronism, glucocorticoid remediable (abst) 1799
Alkalosis, metabolic, Ca2, Mg2 reabsorption (abst). . . . 1789
Allografts. See also Rejection
Banif criteria, pathologicoclinical correlation (abst) 711
Banif criteria validated (abst) 1414
biopsy of, Nephrology Forum 1069
chronic HBV, CsA-treated recipients (abst) 1396
chronic nephropathy and macrophages 57:S-42
delayed function, glomerular ectonucleotidase (abst). . . 1767
detection of donor-specific hyporesponsiveness 1019
function in pregnancy, CsA levels (abst) 700
HBsAg and anti-HCV positive recipients (abst) 699
IL-2 for rejection, IL-4 for tolerance (abst) 1432
increased TGF-f3 expression, CsA toxicity 1634
local irradiation rescue therapy, rejection (abst) 1429
restricted T cell repertoire in rejection 2020
survival, donor/recipient ACE-genotype (abst) 1813
T cell cytokine mRNA quantitation, rejection (abst). . . 1409
Allopurinol, podocyte morphology, PAN (abst) 1400
a-tocopherol supplements, pre-cardiac surgery (abst) . . . . 1402
Alphal-antitrypsin deficiency, anti-PR3 antibodies,
ANCA vasculitis (abst) 1395
Alport syndrome
auditory, ocular and renal abnormalities 1445
collagen IV defects, familial benign hematuria (abst) . . . 330
collagen IV distribution 304
diffuse esophageal leiomyomatosis (abst) 1797
gene therapy, invited lecture (abst) 1779
ocular abnormalities (abst) 1416
psoralen-coupled nucleotide primers 1363
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systemic analysis entire COL4A5 (51 exons) (abst) . . . . 1813
Aluminum, intestinal absorption, iron status and 1879
American Society of Nephrology (ASN) 57:S-1, 57:S-82
Amiloride
-sensitive epithelial Na channel in vivo (abst) 1780
-sensitive Na conductance, rat PT (abst) 1791
Amino acid-based PD solutions 56:S-81
Amino acids
inborn errors of metabolism, PD in crises of (abst) 698
intraperitoneal, nutrition/metabolism (abst) 334
taurine and cysteinesulfinic acid in uremia 1713
Aminoguanidine in preventing diabetic nephropathy 627
Aminopeptidase A (APA)
Ang II, mRNA expression, membranous GN (abst) ... 1768
epitopes, combined mAb, albuminuria (abst) 331
podocytes in culture express (abst) 1769
Amitriptyline, desmopressin, enuresis, children (abst). . . . 1403
Amlodipine/atenolol, drug-resistant hypertension (abst) . . . 335
Ammoniagenesis
hormonal mediators of 15
oral NaHCO3 reduces PT injury (abst) 1807
Ammonium chloride, band 3-positive intercalated CCD
cells 57:S-137
Amylin
binding in PT, Na/water resorption, hypertension
(abst) 1392
renal binding site (abst) 1408
Amyloidosis
dialysis-related, carpal tunnel/hand changes (abst) 1418
dialysis-related, joints, ultrasonography (abst) 1418
dialysis-related, renal transplantation and 282
dialysis-related J32-m 1262
dialysis-related f32-m, modified with carboxymethyl
lysine 1303
renal involvement (abst) 708
Anemia
ACEi-related, transplant recipients 973
CRF, subtherapeutic EPO, IGF-1 937
melatonin metabolism in uremia 653
NO synthases in sickle cell mice 184
Aneurysms, intracranial, PKD, chromosome 4 (abst) 332
Angiogenesis, VEGF expression induces in vivo (abst) . . . 1804
Angiotensin-converting enzyme (ACE)
donor/recipient genotype, allograft survival (abst) 1813
gene polymorphism, renal protection, CRF (abst) 331
gene polymorphism in NIDDM 657
in Goldblatt hypertension (abst) 1407
Angiotensin-converting enzyme (ACE) inhibitors
-related anemia, transplant recipients 973
albuminuria, long-term renal outcome (abst) 1768
chronic treatment, TGF in FHH rats (ahst) 330
endogenous, tissue homogenates and urine (abst) 1769
proteinuria, HCT, dietary salt restriction (abst) 331
structure/function, changes with torasemide (abst) . . . . 1812
Angiotensin 11 (Ang II)
acute short-loop feedback inhibition, renin release
(abst) 1801
Ca2 mobilization, type I Ang hR subtypes (abst) .... 1802
Cl channel and afferent arteriolar constriction 864
depolarizes membrane voltage, glomerular podocytes
(abst) 1817
glomerular number/size, AT1 antagonist (abst) 1407
high glucose, TGF-13, fibronectin, glomerular EC
(abst) 1800
hypertrophy of LLC-PK1, kinase inhibitor p27' 2112
insulin, TGF-pI, matrix mRNAs in mesangial cells 745
intracellular effects in VSMC (abst) 1802
mediates APA up-regulation, mRNA expression, GN
(abst) 1768
NOS, vasoconstriction, after nephrogenesis (abst) 1792
NOS blockade, AT1 and AT2 antagonists, rat (abst)... 1800
plasma EPO, effect in health (abst) 1406
proximal Na/H antiport signaling 1496
Angiotensin II (Ang II) receptors
antagonists, human renoprotection, Nephrology Forum . 684
Na flux, endocytosis, arachidonic acid release, PT. . . 57:S-66
vasopressin receptors, phosphodiesterase inhibition
(abst) 1803
Angiotensin IV (Ang IV) receptors
in human CCD 1125
in human CD cells, evidence for (abst) 1794
Angiotensin receptor antagonist, irbesartan, renal
injury 57:S-132
Angiotensinogen, /3-adrenoceptors and ANG gene 94
Anions
fractional excretion, metabolic acidosis (abst) 706
purification of PT anion exchanger 1914
Anti-DNA autoantibodies, adhesion molecules,
endothelial cells (abst) 1393
Anti-glomerular basement membrane nephritis
CDI 8 and VLA-4, leukocyte migration 462
CD44 expression, rat GN (abst) 1394
as leukocyte mitogen, GN II in rat (abst) 1394
LIF ameliorates 1922
local macrophage proliferation, crescent formation
(abst) 1415
MCP-i mediates glomerular macrophage infiltration.... 665
Tamm-Horsfall protein, nephritogenic potential (abst) . 1423
Anti-hypertensive drugs in early RF, diet (abst) 710
Anti-neutrophil cytoplasmic antibodies (ANCA),
vasculitis, alphal-antitrypsin, anti-PR3 antibodies
(abst) 1395
Anti-Thy-i antibody
-induced GN, L-Arg/NO-pathway, species differences
(abst) 1782
-induced GN, prostaglandins and 190
induces microhematuria, IgAN 1617
induces microhematuria, IgAN (abst) 1798
Antibodies
AECA and AEpCA in transplant recipients (abst) .... 1413
anti-PR3, alphai-AT deficiency, ANCA vasculitis
(abst) 1395
anti-THP, glomerular and interstitial injury (abst) 1399
chronic rHuEPO therapy and immunity, HD 543
deficient IgAi response to nasal CTB in IgAN 952
P-selectin directs autologous, passive Arthus reaction
(abst) 1424
transfected CD59 protects mesangial cells 257
Antigens
autoantigen antigen-derived peptides bound to HLA-
DR15 (abst) 1818
HBs antigenemia in MCNS, clinical management
(abst) 705
renin receptor binding and PAIl antigen 1897
Antihypertensive therapy
progression of NIDDM nephropathy 1641
T/P ratio assessment (abst) 333
Antikaliuresis, TMP-SMX-induced 2063
Antisense oligonucleotides
ICAM-1, reperfusion injury, RF (abst) 1798
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inhibition of ECM accumulation 148
for reperfusion injury 473
Antiviral therapy, nucleoside-analogs block volume-
activated Cl channels (abst) 1788
APACHE III score in ARF, clinical analysis (abst) 702
Apical protein
exposure of tubular cells to (abst) 1782
fibronectin production by human TC 760
Apoptosis
cell proliferation and, obstructive uropathy 200
induced by HMGCoA reductase inhibitors, PT cells
(abst) 1805
induced by low dose CsA in PT cell line (abst) 1805
mesangial cell, cytotoxic drugs and 1565
mesangial cell, LDL modulates 1604
molecular mechanisms (abst) 1811
suppression by integrin, ECM proteins, MC survival
(abst) 1800
thiazides affect distal tubule structure 1180
tubular, acute allograft rejection (abst) 1786
tubular cell death, acute allograft rejection (abst) 1786
Aquaporins
AQP 1 and 2, urinary content in nephrogenic DI
(abst) 1768
AQP2 gene in kidney cells, AVP, cis elements (abst) . . 1816
AQP3 human gene localized to chromosome 9 (abst). . 1781
physiology and pathophysiology (abst) 1811
Arachidonic acid
metabolism inhibitors, IGF-1, PT cells (abst) 1405
regulation of renal Na/K-ATPase activity (abst) 1792
release, PT angiotensin receptors 57:S-66
Arginine vasopressin (AVP)
action in SHR mesangium, LDL effect 1506
aldosterone synergism, Na transport in rat CCD. . . . 57:S-35
AQP2 gene expression in kidney cells, cis elements
(abst) 1816
Arrhythmias with hemodialysis K removal 609
Arterial/cardiac interactions, ESRD 600
Arteriovenous fistula patency, endovascular procedure
for (abst) 1412
Ascorbic acid supplements, pre-cardiac surgery (abst). . . . 1402
Asymptomatic bacteriuria, VUR in children, Nephrology
Forum 312
AT1 antagonist, glomerular number/size (abst) 1407
Atenolol, drug-resistant hypertension (abst) 335
Atherosclerosis, essential hypertension and ET (abst) 707
ATP-sensitive K channel protein ROMK1, imaging by
AFM (abst) 1780
ATP synthesis, skeletal muscle, uremia (abst) 1419
Atractyloside cytotoxicity, mechanism of injury (abst). . . . 1809
Atrial natriuretic peptide (ANP)
acute, chronic volume expansion natriuresis (abst) . . . . 1785
membrane-bound carboxypeptidase A-like activity,
human kidney (abst) 1793
RA stenosis enhances gene expression (abst) 1817
Autocrine/paracrine control of renal phosphate
transport 57:S-148
Autoimmunity
autoantigen antigen-derived peptides bound to HLA-
DRI5 (abst) 1818
autoreactive T cell line, autoimmune GN (abst) 1818
Autonomic neuropathy, cardiovascular mortality in
ESRD (abst) 1769
Autoradiography with [3H1-SR 49059, vasopressin V1
receptor localization 499
Autosomal dominant hypertension, brachydactyly, human
chromosome 12P (abst) 1812
Autosomal dominant polycystic kidney disease (ADPKD)
adults, RBF autoregulation, rat (abst) 1802
CF transmembrane conductance regulator, fluid
secretion 208
chloride/fluid secretion by cultured EC 1327
cyst obstruction 873
evidence for genetic anticipation (abst) 1777
lack of large deletions affecting 3' locus (abst) 1394
matrix metalloproteinases, TIMPs, role in 835
in vitro cyst formation, growth factors (abst) 1782
Autosomal recessive nephrosis, mapping SRN1 to
chromosome 1q25-q31 (abst) 1796
Autosomal recessive polycystic kidney disease (ARPKD),
prenatal diagnosis (abst) 1432
Azathioprine
6-mercaptopurine levels, therapeutic monitoring (abst). 1426
nucleoside-analogs block volume-activated Cl channels
(abst) 1788
Azotemia, neutrophil priming mechanisms 407
B
B cell proliferation, nifedipine reverses 1249
Bacteriuria, asymptomatic, VUR in children, Nephrology
Forum 312
Band 3-positive intercalated cells in CCD 57:S-137
Banif Scores
pathologicoclinical correlation (abst) 711
validation, acute allograft rejection (abst) 1414
Baroreflex control, renin release, hypotension (abst) 332
Basic fibroblast growth factor (bFGF)
expression, remnant kidney model of GS (abst) 1399
as profibrogenic cytokine, renal fibrogenesis (abst) . . . . 1815
f3-adrenoceptors, dexamethasone, ANG gene expression
in OK cells 94
/32-microglobulin (2-m)
amyloid, modified with carboxymethyl lysine 1303
dialysis-related amyloidosis 1262
removal by high-flux HD and HDF (abst) 1434
Betaine
counteracts urea effect on pyruvate kinase 57:S-100
renal synthesis and uptake, localization of (abst) 1791
transporter mRNA, localization and regulation 819
Bezafibrate, blood pressure and renal function (abst). . . . 1801
Biased TCR Vy gene usage by infiltrating yb T cells in
IgAN (abst) 1423
Bicarbonate buffers, CAPD 56:S-75
Bicarbonate dialysate
CVVHD, children (abst) 1412
on-line production, HFD, urea clearance (abst) 1433
phosphate removal and (abst) 1422
Bile acids, obstructive jaundice, renal injury (abst) 1814
Bioelectric impedance analysis, body composition
analysis, HD (abst) 695
Bioimpedance in HD patients 2103
Biopsy, renal
acute renal failure (abst) 704
allografts, Nephrology Forum 1069
CD44 in glomerulonephritis 272
elderly, analysis of (abst) 705
flow cytometric analysis, EC, lymphocytes, post-
transplant (abst) 1792
membrane inserted C5b-9(m) complexes, human
(abst) 1422
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retrospective epidemiologic study, French Caribbean
(abst) 1775
transplant insertion, glomerular PMNs 1409
Blood flow rate, increasing, Kt/V, HD complications
(abst) 695
Blood pressure
arterial, albuminuria in DN, circadian rhythm 579
bezafibrate, renal function and (abst) 1801
chronic volume expansion, vasoactive hormones, CRF
(abst) 1410
diurnal variation, cardiovascular mortality in ESRD
(abst) 1769
early increase in GN, LV malfunction 1321
impaired circadian rhythm, renal failure (abst) 710
long-term NOS inhibition (abst) 1810
postural hypotension, proximal Na handling, high Na
diet (abst) 1426
responses to pregnancy and NO deficiency 1132
T/P ratio assessment (abst) 333
Blood transfusion
donor specific, living unrelated renal transplant (abst) . . 698
donor specific, post-transplant, CsA (abst) 700
Body composition
bioelectric impedance analysis, HD, (abst) 695
changes in children on rHuGH therapy (abst) 1775
Bone cells
phosphate uptake, Hyp mouse 1531
PTH related peptide receptor mRNA expression,
humans (abst) 1798
Bone disease
hypercalcemia, calcitriol, chronic HD (abst) 1433
osteodystrophy, IL-6, IL-6R expression 515
Bone edema, acute, post-transplant (abst) 1419
Bone loss post-transplant, Vit D receptor genotype 1726
Bone marrow transplant, breast cancer and renal
function 1026
Bone metabolism, deflazacort, prednisolone, children,
NS (abst) 709
Bone mineral density (BMD)
deflazacort, children, minimal change NS (abst) 708
dual-energy X-ray absorptiometry (DEXA) in CAPD
(abst) 1418
low, in dialysis patients (abst) 1410
thiazides, human osteoblast-like cell line MG-63 1476
Bowman, Sir William 2120
Bradycardia, HD, autonomic function pattern (abst) 1786
Bradykinin
renal, vasopressin receptors, ligand
selectivity/classification 586
stimulates c-fos expression, growth responses 1850
vasoregulation, developing kidney (abst) 1428
Breast cancer, renal function, chemotherapy, autologous
hematopoietic cell support 1026
Brush border membranes, PKC regulates Nat'H
exchange, rat PT (abst) 1802
C
c-fos, bradykinin stimulates expression, growth responses . 1850
C-reactive protein (CRP) differentiates infection from
rejection (abst) 1792
c-src, MC proliferation (abst) 1784
C5b-9(m) complexes detected in human renal biopsies
(abst) 1422
Cadmium nephrotoxicity (abst) 1804
Calciphylaxis, fatal (abst) 1417
Calcitriol
high phosphorus diet, PTH gene expression 1872
hypercalcemia, bone disease, chronic HD (abst) 1433
PTH, regulate PTH/PTHrP receptors 63
PTH suppression, hypercalcemia, post-transplant
(abst) 1418
PTH suppression in CRF (abst) 709
receptor, effect of Schiff base formation on function. . . 1539
Calcium
-regulated PTH release, secondary
hyperparathyroidism 1834
-sensing receptor, extracellular, Mg renal handling,
Nephrology Forum 2129
CCD reabsorption regulated at apical entry (abst) . . . . 1796
high phosphorus diet, PTH gene expression 1872
Na-Ca exchange in renal arterioles 1856, 1889
reabsorption, prostanoids, CT (abst) 332
reabsorption in TAL, diet, metabolic alkalosis (abst). . . 1789
regulation of a DNA channel 57:S-4
transport, lithium, acute effects (abst) 1406
urinary, PU4, Mg to Cr ratios, children (abst) 1435
Calcium acetate, neutrally and enteric-coated, HD (abst). 1769
Calcium (Ca2)
capacitative influx regulation by high glucose in rat
MC (abst) 1788
intracellular, glucose-induced rise in PMNL, rat 2032
intracellular, hypoxia-induced increase, rat PT (abst) . . . 334
intracellular, in NIDDM 618
intracellular, nifedipine reverses abnormalities 1249
mobilization, Ang II, Ang hR subtypes (abst) 1802
Calcium channels
blockade, renal hemodynamics with NO inhibition, rat
(abst) 1785
blockers, NIDDM nephropathy progression 1641
intact endothelium from renal arteries (abst) 1811
Calcium dialysate
CA125, follow-up, stable CAPD patients (abst) 334
concentrations, CAPD (abst) 1414
long-term low, SHPTH, CAPD (abst) 1434
solutions, CAPD 56:S-92
Calculi
c-myc in mitogenic response to oxalate in LLC-PK, ... 1525
Ca excretion and acute acid load 987
calcium intake, hyperoxaluria (abst) 1433
costs of nephrolithiasis prevention 1706
idiopathic calcium, THP carbohydrate content (abst) . . 1433
Calpain activity, hypoxia-induced, in rat PT 1150
Cancer
breast, renal function and 1026
GM-CSF secretion, human renal cells 1044
Capillary electrophorcsis, tubular fluid, peptide,
electrolyte assays (abst) 1796
Capillary filtration coefficient, refilling rate, high Na
dialysate, HD (abst) 1427
Carbamylated hemoglobin
dialysis adequacy and 1344
in renal failure (abst) 710
Carboxymethyl lysine modifies amyloid 132-m 1303
Carboxypeptidase A-like activity, human kidney, ANP
(abst) 1793
Cardiac output and urea rebound 1273
Cardiac surgery
ARF after, incidence/outcomes/risks (abst) 1402
pre-operative a-tocopherol, ascorbic acid supplements
(abst) 1402
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Cardiovascular function
a-tocopherol, ascorbic acid, pre-cardiac surgery (abst) . 1402
autonomic control in uremia (abst) 1816
cardiac and arterial interactions, ESRD 600
CsA effects, factor VHc, fibrinogen, post-transplant
(abst) 1409
CV diseases in PD patients 56:S-28
EGF and circulatory homeostasis in rat (abst) 1392
glomerular cGMP and PDEs in CHF 1718
homocysteinemia in ESRD 57:S-11
LVM and renal disease, young people 998
mortality with ESRD (abst) 1769
vascular disease, homocysteinemia in ESRD 57:S-11
verapamil-trandolapril combination (abst) 1807
Carpal tunnel/hand changes in amyloidosis (abst) 1418
Cathepsins B, H, and L in proximal tubules, PKD 424
Catheters
CAPD, peritonitis and (abst) 696, 697
CAPD, Seldinger percutaneous technique (abst) 334
swan neck or straight peritoneal (abst) 1411
CD8 leukocyte depletion, HgC12-induced ARF (abst) . . . 333
CD11b and CD14, PD solutions impair expression,
leukocyte adhesion 1676
CDI 8
leukocyte migration/activation, anti-GBM nephritis 462
PD solutions impair expression, leukocyte adhesion . . . 1676
CD44
expression, anti-GBM GN (abst) 1394
expression, mesangial proliferative GN (abst) 1415
in glomerulonephritis 272
in MRL-lpr lupus nephritis 156
tubular expression, T cell-mediated autoimmune TIN
(abst) 1787
CD59
human, expression by transgenic mice (abst) 1413
transfected CD59 protects MC 257
Cell adhesion
galactose binding protein on EC 754
integrins av133 and a51 on human MC (abst) 1820
Cell cycle
control by TGF-/31 in glomerular MC (abst)
protein changes during MPGN
Cell death, programmed. See Apoptosis
Cell growth and Na11H antiporter activity
Cell membrane, Cl channel 'CLN dislocation from
cytosol, volume stress (abst)
Cell volume
ATP-dependent Cl channel, CCD (abst)
control by raffinose, mannitol, sucrose, transplant
preservation fluid (abst)
hyponatremia and ICF volume, K excretion
regulatory ion transport, neutrophil leukocyte
migration (abst)
stress, Cl channel 'CLN dislocation from cytosol to cell
membrane (abst)
ureteric bud cells activate whole cell C1 conductance
(abst)
Cerebrovascular disease in chronic HD
Chemokines, LIF, IL-6, oncostatin M regulate, in MC
(abst)
Chemotherapy, breast cancer and renal function
Children
acute renal failure (abst) 694
ARF, prognostic factors (abst) 694
bacteriuria, asymptomatic, and VUR, Nephrology
Forum 312
bicarbonate dialysate in CVVHD (abst) 1412
body composition changes, rHuGH therapy (abst) .... 1775
CAPD, clinical study (abst) 698
dialysis, transplantation, 25-year study (abst) 1432
inherited disorders, combined liver/renal (abst) 1431
lipid peroxidation in ESRD 1268
low dose s.c. rHuEPO, CRF (abst) 1420
LVM and renal disease 998
minimal change NS, deflazacort, bone mineral density
(abst) 708
molecular genetics, IgAN and HS nephritis (abst) 704
nocturnal enuresis, amitriptyline, desomopressin (abst). 1403
NS, deflazacort, prednisolone, bone metabolism (abst). . 709
NS, IGFBPs (abst) 709
outcome of CRF and ESRD (abst) 1428
renal damage in pyelonephritis (abst) 1427
transplantation, cooperative study, Korea (abst) 699
urinary P04, Mg, Ca to Cr ratios (abst) 1435
UTI, investigation of (abst) 1403
UTI, photon defect on DMSA renal scan (abst) 706
Chloride
acute depletion, afferent arteriolar response to high K
(abst) 1785
intracellular pH recovery in RBC, CRF (abst) 1790
purification of PT anion exchanger 1914
Chloride channels
cell swelling activates ATP-dependent, CCD (abst). . . . 1812
fluorescence-optical evaluation with diHMEQ (abst). . . 1791
'CLN' dislocation from cytosol to cell membrane,
volume stress (abst) 1780
permeable to organic anions, Na/Pi-1 induces (abst). . . 1796
role in afferent arteriolar constriction 864
ureteric bud cells activate conductance, hypotonic
stress (abst) 1791
volume-activated, blocked by nucleoside analogs in
antiviral therapy (abst) 1788
Cholera toxin subunit B, deficient IgAl response in
IgAN 952
Cholesterol
estradiol, LDL, fibrinogen, hypertriglyceridemia, NS
(abst) 1808
renal emboli, clinical presentation/outcome (abst) 1430
Chondrocytes, abnormal growth in CRF 400
Chronic obstructive uropathy, cell proliferation and
apoptosis 200
Chronic renal failure (CRF)
abnormal chondrocyte growth in 400
anemia, subtherapeutic EPO, IGF-1 937
calcitriol, PTH suppression (abst) 709
children, low dose s.c. rHuEPO (abst) 1420
children with ESRD, outcome (abst) 1428
chronic volume expansion, BP, vasoactive hormones
(abst) 1410
C1-HC03 and Na/H exchange, intracellular pH
in RBC (abst) 1790
cytotoxicity of reabsorbed protein (abst) 1399
EPO in, Nephrology Forum 1373
LPL deficiency 1928
M-CSF involvement in uremia 1007
malondialdehyde, SOD, HD (abst) 696
non-diabetic, ACEi gene polymorphism,
renoprotective therapy (abst) 331
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PTH secretion in 1700
serotonin concentration (abst) 710
Chronic renal insufficiency (CR1), melatonin metabolism
in uremia 653
Circadian rhythm
arterial BP, albuminuria in DN 579
impaired, BP, renal failure (abst) 710
Cirrhosis. See Liver cirrhosis
Clarithromycin induces CsA toxicity (abst) 1395
Coagulation, dyslipidemia, renal disease (abst) 1417
COL4A5
gene mutation, type IV collagen, Alport syndrome 304
psoralen-coupled nucleotide primers 1363
systemic analysis, entire coding region (51 exons)
(abst) 1813
COL4A6 gene alterations, in SMC proliferation (abst)... 1797
Cold storage injury and DFO, mouse PT 2109
Collagen IV
abnormalities, GBM, hereditary nephritis (abst) 1398
Alport syndrome, distribution in 304
Alport syndrome, familial benign hematuria (abst) 330
lipid peroxidation, collagen mRNA expression in MC. . 1582
MMP inhibition of 72-kDa type IV collagenase, MC
proliferation (abst) 1431
Collagen synthesis, sex hormones and MC behavior 1173
Collagen VIII produced by normal mammalian glomeruli
(abst) 1398
Compensatory renal growth, CsA (abst) 711
Complement
C2, C3, C4 synthesis, human PT epithelial cells (abst) . 1819
CSb-9(m) complexes detected in human renal biopsies
(abst) 1422
factor B regulated expression, human kidney 521
synthesis by human MC, CMV effects (abst) 1819
transfected CD59 protects mesangial cells 257
Computer-assisted continuous venovenous hemofiltration
(abst) 1425
Conductimetric method, HD quality control (abst) 1774
Congenital urinary tract anomalies, prenatal
ultrasonography (abst) 706
Congestive heart failure, glomerular cGMP and PDEs. . . 1718
Connecting tubules, prostanoids, Ca2 reabsorption
(abst) 332
Continuous ambulatory peritoneal dialysis (CAPD)
adequacy of PD and nutrition 56:S-56
amino acid-based solutions 56:S-81
buffers 56:S-75
Ca dialysate CA125 follow-up (abst) 334
Ca dialysate concentrations (abst) 1414
Ca dialysate long-term, SHPTH (abst) 1434
Ca dialysate solutions 56:S-92
cardiac risk in PD patients 56:S-28
catheters, Seldinger percutaneous technique (abst) 334
children (abst) 698
creatinine appearance index assesses compliance
(abst) 1434
dialysis dose, lean body mass (abst) 697
dual-energy X-ray absorptiometry (DEXA) in CAPD
(abst) 1418
fat free mass measurement (abst) 1420
fibroblasts and peritoneal inflammation control 56:S-22
glucose polymer dialysate 979
granulocyte response in CAPD effluent 643
growth hormone and amino acids 229
HA synthesis by peritoneal mesothelial
cells (abst) 1804, 1814
hypercalcemia, compared to HD (abst) 695
hypertension and LVH 56:S-37
IL-113, hyaluronan synthesis, peritonitis 1337
inflammation in vivo, effluent and 56:S-12
intraperitoneal amino acids, nutrition/metabolism
(abst) 334
leukocyte recruitment into the peritoneum 56:S-17
limitations of 56:S-69
lipoprotein metabolism abnormalities 56:S-41
monocyte/macrophage adhesive behavior (abst) 1393
osmotic agents 56:S-86
outcome after transplant failure (abst) 696
peritoneal function, preservation of 56:S-62
peritoneal function changes (abst) 1421
peritoneal transport and RBF 56:S-47
peritonitis, fungal (abst) 697
peritonitis, GI function post-transplant (abst) 1420
peritonitis, methicillin-resistant Staphylococcus (abst) . . . 696
peritonitis, mortality risk factors, catheter removal
(abst) 696
peritonitis, prolonged catheter implantation (abst) 697
peritonitis after cessation (abst) 1411
peritonitis in Aboriginal/non-Aboriginal patients (abst). 1411
pre-existing liver cirrhosis, ESRD (abst) 697
predictors of technique failure (abst) 1421
survival compared, intermittent HD (abst) 1432
taurine and cysteinesulfinic acid in uremia 1713
TNF receptors on mesothelial cells 219
transcellular pores, UFC of peritoneal membrane
(abst) 1771
Continuous arteriovenous hemodiafiltration (CAVHD)
heparin, filter coagulation vs. patient hemorrhage
(abst) 1770
renal survival, ARF (abst) 1770
Continuous peritoneal dialysis (CPD), serum albumin,
urea clearance 243
Continuous veno-venous hemodiafiltration (CVVHD)
bicarbonate dialysate, children (abst) 1412
computer-assisted reinfusion system (abst) 1425
Contrast media, iohexol saturable absorption, GFR
(abst) 333
Cortical collecting ducts (CCD)
aldosteronc and Nat'H exchange (abst) 1789
Ang IV receptor, human evidence for (abst) 1794
Ang IV receptors in human 1125
AVP-aldosterone synergism, Na transport 57:S-35
axial distribution, band 3-positive intercalated cells. 57:S-137
basolateral and apical Na/H exchangers, human
(abst) 1788
Ca reabsorption regulated at apical entry (abst) 1796
cell swelling activates ATP-dependent Cl channel
(abst) 1812
immortalized rat CCD cells 367
intracellular Na, Na reabsorption (abst) 1795
moxonidine inhibits Nat'H exchange (abst) 1780
vasopressin regulates intracellular Na 57:S-57
Cost-utility of renal transplantation 235
Countercurrent multiplication system, urine
concentration 57:S-93
Creatinine
appearance index assesses CAPD compliance (abst). . . 1434
elevated plasma levels, neonates (abst) 1435
kinetics estimate LBM, in health and PD (abst) 1770
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urinary P04, Mg, Ca to Cr ratios, children (abst) 1435
Cyclic adenosine monophosphate (cAMP)
-activated chloride conductance regulator, molecular
cloning of (abst) 1779
circulating, as hepato-renal link in PT reabsorption
(abst) 1790
CREB phosphorylation, activation of CRE 805
endothelin and renin gene expression 108
inhibition of mesangial MAPK cascade 384
Na/K-ATPase activity, phosphorylation, cortical
tubules (abst) 1435
PTH-related protein in renal vasculature 1591
PTH-related protein in renal vasculature (abst) 1785
urea inhibits production in MTAL 26
Cyclic GMP (cGMP)
glomerular, and PDEs in CHF 1718
inhibition of mesangial MAPK cascade 384
Cyclin kinase inhibitor p27K, Ang Il-stimulated LLC-
PK1 hypertrophy 1789
Cyclosporine (CsA)
-induced hypertension, ET dysfunction (abst) 1408
chronic HBV in allograft recipients (abst) 1396
compensatory renal growth, uninephrectomized rats
(abst) 711
donor specific transfusion, immunologic alterations
(abst) 700
effects on Na/K-ATPase in NBL-1 1483
exacerbates experimental vasculitis (abst) 1787
factor VIIc, fibrinogen, CV disease post-transplant
(abst) 1409
5-HT2 antagonism, RBF autoregulation (abst) 1771
FK506 rescue therapy, resistant rejection (abst) 1426
increased NO activity in humans (abst) 1817
levels in pregnancy, allograft function (abst) 700
low dose, induces apoptosis in PT cell line (abst) 1805
misoprostol prevents peptic ulcer disease (abst) 699
P-glycoprotein expression, salt intake (abst) 1786
regulates T cell-epithelial cell adhesion, LFA-1,
ICAM-1 45
renal Na/K-ATPase, hyperkalemia, thyroxine (abst) . . . . 701
renal Na/K-ATPase expression (abst) 701
renal PAl-I distribution, serum lipids (abst) 1769
suppresses IL-1-induced NOS expression, rat MC
(abst) 1816
transepithelial resistances in MDCK and LLC-PK1
cells (abst) 1789
in transplantation, nine-year experience (abst) 1395
VCAM-1 expression, MC and endothelial cells (abst). . . 701
Cyclosporine (CsA) nephrotoxicity
chronic 1089
clarithromycin induces (abst) 1395
compared, rapamycin and FK506 nephrotoxicity 1110
ECM degradation in (abst) 1401
endothelins and TGF-13 roles (abst) 1792
increased tubular expression of TGF-/3, human
allografts 1634
thromboxane synthetase inhibitor (abst) 700
ysteinesulfinic acid and taurine in uremia 1713
Cystic fibrosis transmembrane conductance receptor
(CFTR)
cAMP-activated, molecular cloning and expression of
(abst) 1779
fluid secretion, ADPKD 208
inhibits epithelial Na conductance (abst) 1811
Cytochrome P-450 in oxidant injury 1118
Cytokines
bFGF as profibrogenic cytokine, renal fibrogenesis
(abst) 1815
gene expression in MRL//pr mice 85
human intrinsic glomerular MC regulate expression
(abst) 1805
stimulus-dependent control of MC survival (abst) 1815
T cell-mediated autoimmune TIN, tubular CD44
(abst) 1787
Thl/Th2, role in experimental vasculitis (abst) 1787
Cytomegalovirus (CMV)
acyclovir prophylaxis, high-risk transplant 57:S-62
chronic allograft rejection, ICAM-1 526
complement synthesis, human MC (abst) 1819
detection of HCMV DNA in plasma, post-transplant
(abst) 1774
immunocytochemical assay, peripheral blood (abst) . . . . 711
Cytotoxic drugs and mesangial cell apoptosis 1565
Cytotoxicity of reabsorbed protein, proteinuric CRD
(abst) 1399
D
Deferoxamine, cold storage injury protection, PT 2109
Deflazacort (Calcort)
bone metabolism, children, NS, prednisolone (abst) .... 709
bone mineral density, children, minimal change NS
(abst) 708
Dendritic cells, human renal, immunomorphological
characteristics (abst) 1793
Denys-Drash syndrome, aberrant proteoglycan
composition in GBM (abst) 1813
Desmopressin, amitriptyline, nocturnal enuresis in
children (abst) 1403
Dexamethasone
J3-adrenoceptors, ANG gene expression in OK cells 94
iNOS expression, IL-1/3-stimulated MC (abst) 1804
Dextran
-induced mesangioproliferative GN, IgA deposits
(abst) 1808
-induced nephropathy, characterized (abst) 1808
Diabetes
-associated gene isolated, GK rat kidneys (abst) 1781
-associated gene isolated, rat kidneys (abst) 1806
DM type II, hyperlipidemia patterns in NS (abst) 705
glomerular hyaluronan synthesis 40
glucagon role in hyperfiltration (abst) 1798
heparin inhibits TGF-f31 renal overexpression (abst). . . 1807
Na/myo-inositol cotransporter 1202
Diabetes insipidus (Dl)
congenital nephrogenic, V2 receptor gene (abst) 335
nephrogenic, urinary content of AQP1 and 2 (abst) . . . 1768
Diabetic nephropathy (DN)
ACE gene polymorphism 657
AGEs in pathogenic process (abst) 1415
aldose reductase pathway role (abst) 1404
aminoguanidine in preventing 627
antihypertensive therapies compared 1641
arterial BP, albuminuria, circadian rhythm 579
cell aging in 250
glucose primes for TGF-pl synthesis, human PT cells.. 1546
growth hormone mediates 506
HMG-CoA reductase inhibition, TGF-f31 mRNA
expression (abst) 708
hyperglycemia, intestinal/renal glucose transport 1101
IgA mesangial nephropathy in (abst) 1777
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risk factors and progression in IDDM 1651
Dialysate
bicarbonate, CVVHD, children (abst) 1412
bicarbonate, effect on phosphate removal (abst) 1422
bicarbonate, on-line infusate production, HFD, urea
clearance (abst) 1433
Ca, long-term low, SHPTH, CAPD (abst) 1434
Ca, low or high, CAPD 56:S-92
Ca concentrations compared, CAPD (abst) 1414
CA125, follow-up, stable CAPD patients (abst) 334
glucose polymer based, peritoneal transport 979
high Na, refilling rate, capillary filtration coefficient
(abst) 1427
PD solutions impair leukocyte adhesion 1676
proportioner to calculate urea clearance (abst) 1412
simplified collection, Kt/V, HD (abst) 1427
Dialysis. See also Hemodialysis; Peritoneal dialysis
-related amyloid and renal transplantation 282
ATP synthesis, skeletal muscle, uremia (abst) 1419
carbamylated hemoglobin and adequacy in ESRD 1344
cardiac output and urea rebound 1273
children, 25-year study (abst) 1432
clinical course of ARF (abst) 703
elderly, quality of life (abst) 1421
enalapril and simvastatin, safety/efficacy (abst) 1410
endotoxin level in systems (abst) 695
HCV, method and evolution of infection (abst) 696
hospitalization rates, USRDS tables 571
low BMD (abst) 1410
membranes and morbidity 1293
renal handling K, residual renal function (abst) 334
taurine and cysteinesulfinic acid in uremia 1713
Dialysis dose
cause-specific mortality and, HD 557
creatinine appearance index assesses CAPD
compliance (abst) 1434
fractional direct dialysis quantification, HD 1845
by liters of blood to process (abst) 1776
mortality and, HD 550
preservation of lean body mass, CAPD (abst) 697
reproducibility of PD adequacy studies 267
Diet
in early RF, anti-hypertensive drugs (abst) 710
high Na, proximal Na handling, postural hypotension
(abst) 1426
high phosphorus PTH gene expression 1872
hypercholesterolemia, interstitial fibrosis 1139
low magnesium, Mg2 reabsorption, TAL, metabolic
alkalosis (abst) 1789
Differential display reverse transcriptase PCR,
glomerular disease (abst) 1398
Diffuse esophageal leiomyomatosis, Alport syndrome
(abst)
diHMEQ, fluorescence-optical evaluation, Cl channel
(abst)
Distal convoluted tubule, thiazides provoke apoptosis
Diuretics
loop, hypoxemia-induced renal vasoconstriction (abst) . 1436
thiazides and MG-63 1476
Diurnal BP variation, cardiovascular mortality in ESRD
(abst) 1769
DMSA (dimercaptosuccinic acid)
effect on nephrosclerosis, ROS, rat 1572
renal scan, photon defect in children with UTI (abst). . . 706
DNA
Ca2 regulation, cell surface nucleic acid channel. . . . 57:S-4
synthesis, lovastatin, PDGF, EGF (abst) 707
Donor kidneys
detection of donor-specific hyporesponsiveness 1019
living-related transplant, mortality (abst) 699
living-related transplant for IgAN, prognosis (abst). . . . 1425
living unrelated, donor-specific blood transfusion
(abst) 698, 700
Swiss Living Kidney Donor Registry since 1993 (abst). . 1436
Dopamine
oliguric renal failure of HFRS (abst) 701
"renal-dose" for ARF 4
Doppler scanning in renovascular disease 1288
Dual-energy X-ray absorptiometry (DEXA) bone
densitometry, CAPD (abst) 1418
Duke University Medical Center (Durham, NC). 57:S-1, 57:S-2
Dyslipidemia, coagulation, fibrinolysis, renal disease
(abst) 1417
Dyslipoproteinemia post-transplant, fluvastatin (abst).... 1409
E
Early growth response gene-i in nephritis, MC
proliferation (abst) 1815
Echocardiography, volume status, HD and (abst) 1412
ECTO-5 '-nucleotidase, multidrug resistance activity in
EC (abst) 1803
Ectoenzymes, glomerular cell, glucocorticoids regulate
(abst) 1805
Ectonucleotidase, altered glomerular, delayed graft
function (abst) 1767
Elastase enhances IL-8 production in endothelial cells
(abst) 1767
Elderly
acute renal failure (abst) 693
Pi reabsorption in aging, cellular mechanisms 855
quality of life and dialysis (abst) 1421
renal biopsy, analysis of (abst) 705
Electron beam computed tomography (EBTC) assesses
tubular dynamics 1358
Electrophysiological analysis, peritoneal permeability,
peritonitis (abst) 1788
1 1-hydroxysteroid dehydrogenase (OHSD), liver
cirrhosis (abst) 1431
ELK, renal development and microvascular endothelial
assembly 57:S-73
Emboli, renal cholesterol (abst) 1430
Enalapril
glomerular number/size, postnatal rats (abst) 1407
hydrochlorothiazide, drug-resistant hypertension (abst). . 335
safety/efficacy in dialysis (abst) 1410
End-stage renal disease (ESRD)
CAPD with pre-existing liver cirrhosis (abst) 697
cardiac and arterial interactions 600
cardiovascular mortality (abst) 1769
children, lipid peroxidation in 1268
children with CRF, outcome (abst) 1428
dialysis adequacy and carbamylated hemoglobin 1344
dialysis mode, evolution of HCV infection (abst) 696
homocysteinemia, vascular disease 57:S-1 I
IDDM and, 35-year follow-up 2041
international comparison of mortality 1013
nutritional status 343
sleep apnea and (abst) 1421
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Endocytosis
albumin, megalin as receptor for (abst) 1799
albumin, receptor mediated by GTP-binding protein
(abst) 1799
PT angiotensin receptors, Na flux 57:S-66
renal type II Na/P1 -cotransporter, PTH (abst) 1800
Endogenous serum antioxidants, serum lipid peroxide,
HD (abst) 694
Endothelial cells
anti-DNA autoantibodies, adhesion molecule
expression (abst) 1393
antibodies in transplant recipients (abst) 1413
antibodies to, IgAN and lupus nephritis (abst) 1395
Ca dependent ion channels, renal arteries (abst) 1811
contraction by H202, tissue damage (abst) 1795
glomerular, thrombin, MCP-1 expression, PKC (abst). . 1806
human glomerular, verotoxin-1 effects (abst) 335
human glomerular microvascular, verotoxin-i effects
(abst) 1808
microvascular, ELK, LERK-2 in developing kidney.. 57:S-73
mixed lymphocyte culture supernatant, CsA, VCAM-1
(abst) 701
neutrophil enzymes enhance IL-8 production (abst) ... 1767
permeability, high glucose, PKC-a activation (abst). . . . 1803
prostacyclin, ET-1 secretion, human pregnancy (abst). .1397
rHuEPO enhances PAl-i production 102
signal transduction of EPO 481
Endothelin-1 (ET-1)
1,2-diacyiglycerol generation, rat PT 1794
nonpeptide orally active receptor antagonist (abst) . . . . 1407
receptor antagonist in nephritis 962
receptor subtypes localized, normal and remnant rat
kidney (abst) 1392
renal expression, passive Heymann nephritis (abst). . . . 1815
renal function, misoprostol, post-transplant (abst) 700
rHuEPO and vasoconstrictor tone 1255
secretion, endothelial cells, human pregnancy (abst). . . 1397
Endothelin (ET)
-mediated phospholipid signaling in rat PT (abst) 1795
cAMP-induced renin gene expression 108
central effects, renal excretory function (abst) 1809
CsA nephrotoxicity, role in (abst) 1792
dysfunction in CsA-induced hypertension (abst) 1408
endogenous, renal vascular effects, rat (abst) 1784
essential hypertension and atherosclerosis (abst) 707
plasma, rHuEPO, maintenance HD (abst) 694
receptors in rat renal medulla 135
renal ischemia/reperfusion pathophysiology 776
in renal pathophysiology 1827
systemic in primate pregnancy, preeclampsia (abst). . . . 1408
Endotoxin level in dialysis systems (abst) 695
Endovascular procedure, maintain AV fistula patency
(abst) 1412
Eosinophil activation, IL-2R, Henoch-SchOnlein purpura,
IgAN (abst) 704
Epidermal growth factor (EGF)
AP-1 cascade up-regulation, post-nephrectomy, Na
intake, rat (abst) 1799
circulatory homeostasis (ahst) 1392
DNA synthesis, lovastatin, cell proliferation (abst) 707
heparin-binding, mRNA expression in MC, Thy 1.1
model (abst) 1415
IL-6/EGF ratio, acute/chronic renal damage (abst) . . . . 1819
tubular proliferation, experimental GN (abst) 1400
urinary IL-6/EGF ratio, IgA nephropathy 1990
Epiphyseal chondrocyte growth in CRF 400
Epithelial cells (EC)
amiloride-sensitive Na channel in vivo (abst) 1780
antibodies in transplant recipients (abst) 1413
antibodies to, IgAN and lupus nephritis (abst) 1395
c-myc in mitogenic response to oxalate in LLC-PK1 . . . 1525
CFTR and fluid secretion in PKD 208
CFTR inhibits Na conductance (abst) 1811
complement regulation by human PT (abst) 1819
CsA effects on Na/K-ATPase in NBL-1 1483
CsA regulates adhesion, LFA-1, ICAM-1 45
ECTO-5'-nucleotidase, multidrug resistance (abst) . . . . 1803
flow cytometric analysis, biopsy post-transplant (abst). . 1792
glomerular, interact with MMPs (abst) 1806
glomerular visceral, high glucose, Ang II, fibronectin,
TGF-/3 (abst) 1800
Na channel mutations cause pseudohypoaldosteronism
type I (abst) 1795
Na channel regulation by aldosterone, A6 kidney cells
(abst) 1783
omega-3 fatty acids and GEC injury 1863
PKC inhibits Na pump current in A6 cell epithelia
(abst) 1796
secretion by ADPKD in cultured human 1327
transepithelial resistances in MDCK and LLC-PK1
cells with CsA (abst) 1789
tubular, aggregates, morphology and integrin
expression (abst) 1786
tubular, CD44 in MRL-lpr lupus nephritis 156
tubular, galactose binding protein on EC 754
tubular, iron and renal tubular cell toxicity 436
tubular, proliferation and EGF in GN (abst) 1400
Erythrocyte zinc-protoporphyrin as iron-deficiency
indicator (abst) 1428
Erythropoietin (EPO)
Ang II infusion in health (abst) 1406
in CRF, Nephrology Forum 1373
direct action on VSMC (abst) 1809
iron-deficiency indicators for therapy (abst) 1428
iron supplementation with 1694
melatonin metabolism in uremia 653
production, post-hemorrhage, renal sympathetic nerve
activity (abst) 1818
production post-ischemic ARF 1958
rHuEPO, effect on immunity, chronic HD 543
rHuEPO, low dose s.c., children, CRF (abst) 1420
rHuEPO, PAl-i production in endothelial cells 102
rHuEPO, plasma endothelin, maintenance HD (abst). . . 694
signal transduction, endothelial cells 481
subtherapeutic, IGF-1, anemia, CRF 937
tyrosine phosphorylation 481
Escherichia coli, clearance factor for S fimbriated, THP
(abst) 1809
Esophageal leiomyomatosis, Alport syndrome and (abst) . 1797
Essential hypertension (EH)
atherosclerosis and ET (abst) 707
SHR- and WKY-derived PT cell lines 125
Estradiol, LDL, fibrinogen, hypertriglyceridemia, NS
(abst) 1808
Extracellular calcium-sensing receptor, Ca and Mg renal
handling, Nephrology Forum 2129
Extracellular matrix (ECM)
accumulation suppressed in GN 148
degradation in CsA nephrotoxicity (abst) 1401
expansion in high IgA strain of ddY mouse 1946
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galactose binding protein on EC
MC survival, integrin-mediated apoptosis suppression
(abst)
spatial organization modulates osteopontin in MC
(abst)
F
Factor B, Factor H synthesis, human PT epithelial cells
(abst) 1819
Factor VIIc, CsA, CV disease, post-transplant (abst) . . . . 1409
Fat free mass measurement, CAPD (abst) 1420
Fibrinogen
CsA effects, CV disease, post-transplant (abst) 1409
estradiol, LDL, hypertriglyceridemia, NS (abst) 1808
Fibrinolysis
dyslipidemia, renal disease (abst) 1417
Lp(a) levels with NS (abst) 709
Fibroblasts
cell growth and Na/H antiporter activity 1684
intracellular calcium in NIDDM 618
peritoneal inflammation control in PD 56:S-22
Fibrogenic growth factors, monocyte/macrophage
infiltrate in GN (abst) 1393
Fibronectin
glomerular hyaluronan synthesis in diabetes 40
high glucose, Ang II, TGF-p, glomerular visceral EC
(abst) 1800
isoforms in immune complex nephritis 908
production by human tubular cells, apical protein
effect 760
Filtration slit and podocyte plasma membrane 54
5-HT2 antagonism, RBF autoregulation, CsA-treated rats
(abst) 1771
FK506 (tacrolimus)
exacerbates experimental vasculitis (abst) 1787
nephrotoxicity, compared to rapamycin and CsA 1110
rescue therapy, rejection under CsA (abst) 1426
Flow cytometric analysis, renal EC, graft-infiltrating
lymphocytes, biopsy post-transplant (abst) 1792
Fluid reabsorption rate in PCT, HgCI2 (abst) 1788
Fluorescence-optical evaluation C1 channel with
diHMEQ (abst) 1791
Fluoroquinolone-associated tendon rupture, tendinitis
(abst) 1429
Fluvastatin, dyslipoproteinemia post-transplant (abst). . . . 1409
Focal and segmental hyalinosis and sclerosis (FSHS) in
lgAN (abst) 1417
Focal segmental glomerular sclerosis (FSGS)
enigma of 57:S-119
glomerular hypertrophy, PAN-treated rats 768
idiopathic collapsing 1734
Foot process effacement in acute PAN 1278
14 kDa galactosc binding protein on human EC 754
Fractional direct dialysis quantification, HD 1845
Fungal peritonitis in CAPD (abst) 697
Furosemide
microinjection technique studies tubular site of action
(abst) 1787
oliguric renal failure of HFRS (abst) 701
G
G-protein binding protein receptor mediated
albumin cndocytosis (abst) 1799
Galactose binding protein on cpithelial cells 754
Galectin-i on human tubular EC 754
754 Gangliosides
cell surface, signal transduction, rat podocytes (abst) . . 1794
1800 GM2 activator protein gene expression (abst) 1406
"Gastric" H/K-ATPase u subunit gene, hypokalemia
1783 (abst) 708
Gastrointestinal function post-transplant, peritonitis,
CAPD (abst) 1420
Gene therapy, Alport syndrome, invited lecture (abst) . . . 1779
Genetics
13-adrenoceptors and ANG gene 94
2q13 region deletions, juvenile nephronophthisis (abst). 1795
ACE gene polymorphism in NIDDM 657
ACEi gene polymorphism, renoprotective therapy,
CRF (abst) 331
ADPKD, evidence for anticipation in (ahst) 1777
ADPKD, lack of large deletions affecting 3' locus
(abst) 1394
aldosteronism, glucocorticoid remediable (abst) 1799
Alport syndrome, systemic analysis entire COL4A5 (51
exons) (abst) 1813
AQP2 gene expression, AVP, cis elements (abst) 1816
AQP3 localized to chromosome 9, human (abst) 1781
c-myc in mitogenic response to oxalatc in LLC-PK1 . . . 1525
combined liver/renal disorders, children (abst) 1431
Cux-1 expression in the kidney 453
cytokine gene expression in MRL/lpr mice 85
diabetes-associated gene isolated, rat kidney (abst). . . . 1806
diabetes-associated gene isolated from GK rat kidneys
(abst) 1781
Egr-i expression, nephritis, MC proliferation (abst) . . . 1815
endothelin and renin gene expression 108
familial optic nerve coloboma, with renal disease
(abst) 1776
Gal alpha 1,3 Gal as dominant xenoantigen (abst) . . . . 1413
ganglioside GM2 activator protein gene expression
(abst) 1406
glomerular transgene activity, generation of reversible
switches (abst) 1816
hereditary Clq deficiency, nephritis, SLE, IgAN 635
human CD59 expression by transgenic mice (abst) . . . . 1413
hypertension, brachydactyly, human chromosome 1 2P
(abst) 1812
inborn errors of metabolism, PD in crises of (abst) 698
intracranial aneurysms, PKD, chromosome 4 (abst) . . . . 332
localization of Kid-i like gene, human genome (abst). . 1797
mapping/characterization, DNase I hypersensitive sites,
MCP-1 (abst) 1815
mapping SRN1 to chromosome 1q25-q31, idiopathic
NS (abst) 1796
molecular cloning, 2q13 region, ncphronophthisis
(abst) 1813
mouse bpk and jcpk are allelic 1158
riephrogenesis, embryonic renal marker sequences
(abst) 1781
nephrogenic Dl, V2 receptor gene (ahst) 335
Pax-2 and WT1 expression in induced ATN (abst) . .. . 1781
polycystic kidney disease, rescue of 1240
primary renal defects in hypertension 717
RAS, polymorphisms of 732
regulation of stromelysin by IL-113 894
Reni" gene, targeting construct built with homology
(abst) 1811
renal involvement, von Hippel-Lindau disease 944
renin gene transcription initiated, start site, rat (abst). . 1806
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(abst) 1394
transcriptional control by AGEs 1166
transgenesis, study gene function/model human
pathology (abst) 1795
Genotypes, donor/recipient ACE, allograft survival (abst). 1813
Gentamicin-induced renal failure, NOS (abst) 1782
Glomerular basement membrane (GBM)
aberrant proteoglycan composition, Denys-Drash
syndrome (abst) 1813
collagen IV abnormalities, hereditary nephritis (abst) . . 1398
heparin, heparinoids prevent immune complex binding. 1555
Glomerular cells
ectoenzymes regulated by glucocorticoids (abst) 1805
high glucose, Ang II, fibronectin, TGF-J3 (abst) 1800
human intrinsic mesangial, cytokine expression (abst). . 1805
human microvascular endothelial, verocytotoxin-1
effects (abst) 335
mesangial, hyaluronan synthesis in diabetes 40
Glomerular disease
albuminuria and integrin expression 1310
deposits in lupus nephritis, nucleosomes and histones
in (abst) 1767
differential display reverse transcriptase PCR (abst) . . . 1398
tubular proteinuria,.interstitial fibrosis (abst) 1417
Glomerular ectonucleotidase expression, delayed graft
function (abst) 1767
Glomerular filtration rate (GFR)
assessment methods, preterminal/terminal RF (abst). . . 1777
changes in tubular fluid delivery to macula densa
(abst) 1784
chronic hyperfiltration, acid-base transport, rat loop of
Henle (abst) 1790
glucagon in diabetic hyperfiltration (abst) 1798
predicting post-transplant (abst) 1395
PTHrP intrarenal infusion, RBF, rat (abst) 1802
saturable absorption of iohexol (abst) 333
tumor associated trypsin inhibitor (abst) 1809
Glomerular function
increased NO synthesis, gentamicin-induced RF (abst) . 1782
losartan inhibits TGF-13, hypertensive rats (abst) 1784
method for measuring albumin permeability 1352
modeling ultrafiltration, glomerular resistance (abst). . . 1435
PDGF-mediated prostaglandin G/H synthase-2
expression 71
permselectivity, non-diabetic nephropathy (abst) 1771
responses to pregnancy and NO deficiency 1132
Glomerular hypertrophy in PAN-treated rats 768
Glomerular hypertrophy in PAN-treated rats (abst) 1399
Glomerular injury
anti-THP antibodies (abst) 1399
ET receptor antagonist, proteinuria, nephritis 962
fibronectin isoforms in immune complex nephritis 908
hypertension, predicted by reduced nephron number
(abst) 1798
omega-3 fatty acids, complement-mediated EC 1863
Glomerulonephritis (GN)
anti-GBM, CD18 and VLA-4, leukocyte migration 462
anti-GBM, CD44 expression, rat (abst) 1394
anti-GBM, LIF ameliorates 1922
anti-GBM, local macrophage proliferation, crescent
formation (abst) 1415
anti-GBM, MCP-1, macrophage infiltration 665
anti-GBM, nephritogenic potential of THP (abst) 1423
anti-GBM, THP as leukocyte mitogen, rat (abst) 1394
anti-Thy-i, L-arginine/NO-pathway, species differences
(abst) 1782
CD44 expression 272
CD44 expression, Thy 1.1 model (abst) 1415
crescentic, T cell depletion (abst) 1413
early BP increase and LV malfunction 1321
EGF and tubular proliferation (abst) 1400
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low, enhances NOS activity in rat macrophages (abst). . 1783
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Phosphodiesterase inhibition, vasopressin and Ang hR
interactions (abst) 1803
Phosphodiesterase isoenzymes (PDEs) blunted cGMP
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Polymerase chain reaction (PCR)
differential display reverse transcriptase, glomerular
disease (abst) 1398
Polymorphonuclear leukocytes, glucose-induced rise in
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conductance of PT, regulated by cytosolic pH (abst). . . 1396
depletion, redistribution of H-ATPase, cortical distal
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depletion modulates aldose reductase mRNA, rat
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Prenatal diagnosis, ARPKD (abst) 1432
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E1 inhibits collagen expression in GN 190
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G/H synthase-2, PDGF-mediated expression in MC 71
hypoxemic renal dysfunction (abst) 1427
renin-aldosterone axis, natriuresis (abst) 1407
Prostanoids
Ca2 reabsorption, CT (abst) 332
rHuEPO and vasoconstrictor tone 1255
secretion, placental villous trophoblasts (abst) 1397
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Protease
glycine reduces hypoxia-induced, rat PT (abst) 1782
human, oxidant injury, MCD (abst) 332
hypoxia-induced, glycine, acidosis reduce,
rat PT (abst) 1768
nexin 1, renal expression in mice 1936
Protein
matrix proteins, TGF-/31, chronic rejection 1904
methylation and membrane damage in CRF 358
purification of PT anion exchanger 1914
Protein catabolic rate (PCR), Kt/V factors in
HD (abst) 1422, 1430
Protein kinase C (PKC)
inhibits Na pump current in A6 cell epithelia (abst) . . . 1796
mediates proliferative effect of vascular endothelial GF
(abst) 1794
Na/H exchange in BBM vesicles, rat PT (abst) 1802
PKC-a activation, endothelial cell permeability, high
glucose (abst) 1803
PKC-a mediated by TGF-p, VSMC differentiation
(abst) 1800
regulation of renal Na/K-ATPase activity (abst) 1792
thrombin stimulates MCP-1 gene transcription (abst) . . 1806
Proteinase 3 (PR3)
anti-PR3 antibodies, aiphal-AT deficiency, ANCA
vasculitis (abst) 1395
enhances IL-8 production in endothelial cells (abst) . . . 1767
expression, PMN subset (abst) 1820
Proteinuria
ACEi, HCT and dietary salt (abst) 331
cytotoxicity of reabsorbed protein, chronic renal
disease (abst) 1399
early PAN, glomerular ROS, lipid peroxidation (abst) . 1414
ET receptor antagonist, glomerular lesions, nephritis . . . 962
hypertensive pregnancy (abst) 1392
interstitial inflammation, scarring (abst) 1782
non-diabetic, glomerular permselectivity, skin capillary
permeability (abst) 1771
tubular, interstitial fibrosis (abst) 1417
Proteoglycan, aberrant composition, GBM, Denys-Drash
syndrome (abst) 1813
Proximal tubular cells
1,25(OH)2D3, adhesion molecule expression (abst). . . . 1431
collagen IV-coated porous membranes (abst) 1794
D-glucose effect on cellular phosphates 57:S-30
glycine and oxidant damage 845
HMG-CoA reductase inhibitors induce apoptosis
(abst) 1805
HMG-CoA reductase inhibitors reduce proliferation
(abst) 1805
IGF- 1-induced growth, arachidonic acid metabolism
inhibitors (abst) 1405
low dose CsA induces apoptosis (abst) 1805
myoglobin inhibits HK-2 proliferation 796
Proximal tubules
amiloride-sensitive Na conductance (abst) 1791
amylin binding, Na/water resorption, hypertension
(abst) 1392
Ang II and Na/H antiport signaling 1496
angiotensin receptors, Na flux, endocytosis 57:S-66
circulating cAMP as hepato-renal link in reabsorption
(abst) 1790
circulating GFs, rat cell culture (abst) 1397
cold storage injury and DFO, mice 2109
complement regulation by EC, humans (abst) 1819
ET-1 stimulates 1,2-diacylglycerol (abst) 1794
ET-mediated phospholipid signaling (abst) 1795
glycine, acidosis reduce hypoxia-induced protease
(abst) 1768
glycine reduces hypoxia-induced protease activity
(abst) 1782
hypoxia-induced Ca2 increase (abst) 334
hypoxia-induced calpain activity 1150
K conductance regulated by cytosolic pH (abst) 1396
lysosomal cysteine proteinases in PKD 424
MCP-1 mRNA expression in culture, rat (abst) 1397
moxonidine inhibits Na/H exchange (abst) 1780
oral NaHCO3 reduces injury (abst) 1807
PKC regulates Na47H exchange in BBM vesicles, rat
(abst) 1802
purification of PT anion exchanger 1914
SHR- and WKY-derived PT cell lines 125
tubular fluid analyzed by capillary electrophoresis
(abst) 1796
tubular fluid delivery changes, macula densa, filtration
rate (abst) 1784
PrPcspecific mAb 3F4, T cell costimulation, IL-2R
upregulation (abst) 1426
Pseudohypoaldosteronism type I, epithelial Na channel
mutations (abst) 1795
Psoralen-coupled nucleotide primers, COL4A5
mutations, Alport syndrome 1363
Pulmonary hypertension, renal vasoconstriction (abst) .... 335
Purine nucleotide cycle, hypoxia, rat renal
cortex/medulla 1195
Puromycin aminonucleoside (PAN)
biphasic glomerular hypertrophy 768
glomerular tuft hypertrophy, GS, rat (abst) 1399
podocyte morphology, with tungsten or allopurinol
(abst) 1400
Puromycin arninonucleoside (PAN) nephrosis
foot process effacement 1278
proteinuria, glomerular ROS, lipid peroxidation (abst). 1414
Pyelonephritis
cellular/inflammatory response (abst) 1814
younger age as risk for renal damage (abst) 1427
Pyruvate buffers, CAPD 56:S-75
Pyruvate kinase, GPC and betaine as counteracting
osmolytes 57:S-100
Q
Quality of life, elderly dialysis patients (abst) 1421
R
Raffinose, cell volume control, transplant preservation
fluid (abst) 1780
Rapamycin
experimental vasculitis, Thl/Th2 cytokine role (abst). . . 1787
nephrotoxicity, compared to CsA and FK506 1110
Reactive oxygen species (ROS)
DMSA effect, nephrosclerosis 1572
oxidant induction of tyrosine phosphorylation 164
proteinuria in early PAN, lipid peroxidation (abst) .... 1414
Recombinant human erythropoietin (rHuEPO)
immunity, effect on, chronic HD 543
low dose s.c. children, CRF (abst) 1420
PAl-i production in endothelial cells 102
plasma endothelin, maintenance HD (abst) 694
vasoconstrictor tone, ET-1, prostanoids 1255
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Recombinant human growth hormone (rHuGH)
amino acid profiles, CAPD 229
body composition changes, children (abst) 1775
Red blood cells
CL-HC03 and Na/H exchange, intracellular pH
recovery, CRF (abst) 1790
hypochromic, as iron-deficiency indicators, HD, EPO
(abst) 1428
Reflux nephropathy
long-term follow-up of adults (abst) 1416
in pregnancy 593
Rejection
acute allograft, apoptotic tubular cell death (abst) 1786
acute/chronic, restricted T cell repertoire 2020
Banif criteria validation (abst) 1414
Banif Scores, pathologicoclinical correlation (abst) 711
chronic, altered TGF-j3 expression 489
chronic, TGF-131 and matrix proteins 1904
chronic allograft, CMV, ICAM-1 526
humoral alloactivity in transplantation 1464
IL-2 for rejection, IL-4 for tolerance (abst) 1432
IL-6 and CRP differentiate from infection (abst) 1792
inducible NOS with transplantation 2088
rescue therapy with FKSO6, CsA resistance (abst) 1426
rescue therapy with local irradiation of allografts,
(abst) 1429
T cell cytokine mRNA quantitation, sheep (abst) 1409
RenY' gene, targeting construct built with homology
(abst) 1811
Renal artery intact endothelium, Ca dependent ion
channels (abst) 1811
Renal artery stenosis
detection by magnetic resonance angiography (abst). . . 1776
enhances ANP gene expression (abst) 1817
Renal biopsy. See Biopsy, renal
Renal blood flow (RBF)
autoregulation, ADPKD, rat (abst) 1802
autoregulation, 5-HT2 antagonism, CsA-treated rats
(abst) 1771
cortical/medullary microvascular autoregulation . . . . 57:S-23
NGLarginine, losartan, RBF autoregulation (abst) . .. . 330
NO role in autoregulation, conscious dog (abst) 1817
PTHrP intrarenal infusion, GFR, rat (abst) 1802
Renal development
Ang Il-NOS, vasoconstriction, after nephrogenesis
(abst) 1792
bradykinin and vasoregulation of (abst) 1428
ELK and LERK-2, microvascular endothelial
assembly 5 7:S-73
gene expression, embryonic marker sequences (abst) . . 1781
glucocorticoid effect on mitochondrial pool (abst) 1797
mesonephric function in sheep 1624
MMPs, kidney morphogenesis, renal organogenesis in
vitro (abst) 1797
Pax-2 and WT1 expression, induced ATN (abst) 1781
TGF-f32R mRNA in embryonic rat kidney (abst) 1406
ureteric bud arborization and nephron deficit 783
Renal disease
ACTH lowers serum lipids 538
amyloidosis, involvement in (abst) 708
autonomic nephropathy, CV mortality in ESRD (abst). 1769
dyslipidemia, coagulation, fibrinolysis (abst) 1417
ET role, experimental/therapeutic applications 1827
familial optic nerve coloboma with (abst) 1776
inherited liver/renal disorders, children (abst) 1431
insulin resistance/hyperinsulinemia, Syndrome X (abst). 1417
Laser Scanning Confocal Microscopy in humans (abst). 1401
left ventricular abnormalities, young people 998
MCP-1, monocyte infiltration, pathogenic role (abst) . . 1801
multiple myeloma (abst) 701
octreotide trial, hepatorenal syndrome (abst) 1419
outcome, treatment technologies/tolerance, nutritional
status and 1293
ovarian hyperstimulation syndrome and (abst) 706
pregnancy and (abst) 1430
primary, pregnancy and (abst) 704
primary defects in hereditary hypertension 717
progressive, polymorphisms of RAS 732
in von Hippel-Lindau disease 944
Renal failure. See also Acute renal failure (ARF);
Chronic renal failure (CRF)
antisense oligonucleotides, reperfusion injury 473
antisense oligonucleotides for ICAM-1, reperfusion
injury (abst) 1798
early, diet, anti-hypertensive drugs (abst) 710
gentamicin-induced, increased NO synthesis (abst) . . . . 1782
Gordon's syndrome in a neonate (abst) 1776
impaired circadian rhythm, BP (abst) 710
myeloma (abst) 1420
oxidation of LDL (abst) 1403
pamidronate therapy, hypercalcemia (abst) 1418
petrol sniffing (abst) 1420
preterminal/terminal, GFR assessment methods (abst) . 1777
tubulointerstitial damage as predictor of progression
(abst) 1401
Renal function
asymptomatic Korean adults, mass study (abst) 707
bezafibrate, blood pressure (abst) 1801
breast cancer, chemotherapy, autologous
hematopoietic cell support 1026
excretory, central effects of ET (abst) 1809
glycogen storage disease type I (abst) 1770
hypoxemia-induced dysfunction, NO (abst) 1428
hypoxemia-induced dysfunction, prostaglandins (abst). . 1427
loop diuretics, hypoxemia, renal vasoconstriction
(abst) 1436
misoprostol, ET-1, post-transplant (abst) 700
residual, peritoneal transport, PD 56:8-47
residual, renal handling K, dialysis (abst) 334
tubular acidosis in primary Sjogren's syndrome (abst). . 1403
ularitide (Urodilatin), renal effects (abst) 1818
urinary mass screening, Korea (abst) 707
verapamil-trandolapril combination (abst) 1807
Renal hemodynamics
Ang Il-NOS, vasoconstriction, developing kidney after
nephrogenesis (abst) 1792
Ca channel blockade during NO inhibition, rat
(abst) 1785
Cl channel and vasoconstriction 864
endogenous ET effects, in vivo, rat (abst) 1784
PTH-related protein and NO/cAMP in renal
vasculature 1591
PTH-related protein and NO/cAMP in renal
vasculature (abst) 1785
pulmonary hypertension, renal vasoconstriction (abst). . . 335
Renal hypertrophy, TGF-/3 in compensatory (abst) 1406
Renal injury. See Injury, renal
Renal insufficiency, risk factors/progression in DM 1651
Renal interstitial fibrosis
anti-THP antibodies (abst) 1399
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apical exposure of tubular cells to proteins (abst) 1782
bFGF as profibrogenic cytokine, renal fibrogenesis
(abst) 1815
diet-induced hypercholesterolemia 1139
fibronectin production by human tubular cells 760
myofibroblasts, experimental renal infection (abst) . . . . 1399
SPARC expression, arteriolopathy 1978
tubular proteinuria as marker (abst) 1417
Renal interstitial mucinosis, extension of the concept
(abst) 1401
Renal nerves
antagonism of endogenous adenosine, natriuretic effect
(abst) 1818
sympathetic activity, EPO production post-hemorrhage
(abst) 1818
Renal perfusion pressure, medullary electrolyte
concentration (abst) 1810
Renal scans, DMSA, photon defect in children with UT!
(abst) 706
Renal transplantation. See Transplantation
Renal vasculature
cholesterol emboli, clinical presentation/outcome
(abst) 1430
Doppler scanning in renovascular disease 1288
microvascular RBF autoregulation 57:S-23
Na-Ca exchange in renal arterioles 1856, 1889
parenchymal renal veins (abst) 1401
plasminogen activation and thrombotic
microangiopathy 2011
SPARC in interstitial fibrosis, arteriolopathy 1978
Renin
adrenomedullin in afferent arterioles (abst) 1810
gene expression, ET inhibits 108
gene expression, SOD, acute ischemic injury (abst) 693
gene transcription initiated, single start site, rat (abst) . 1806
receptor binding and PAIl antigen 1897
release, Ang II acute short-loop feedback inhibition
(abst) 1801
release, baroreflex control, hypotension (abst) 332
renal nuclear proteins binding renin promoter 1515
secretion, 02 formation, JG cells, LDL, HDL (abst).. 1801
serum total, IDDM with microalbuminuria 902
Renin-aldosterone axis, natriuresis and prostaglandins
(abst) 1407
Renin-angiotensin system (RAS)
podocytes in culture express APA (abst) 1769
polymorphisms of, progressive renal diseases 732
Renid gene, targeting construct built with homology
(abst) 1811
Renoprotection
ACEi gene polymorphism, non-diabetic CRF (abst) 331
human, Ang hR antagonists, Nephrology Forum 684
irbesartan reduces renal injury 57:S-132
Robinson, Dr. Roscoe R. "Ike 57:S-1, 57:S-2, 57:S-50,
57:S-82, 57:S-105
ROMK1, imaging by atomic force microscopy (abst) .... 1780
S
Salt intake
ACEi, HCT, proteinuria (abst) 331
CsA-induced P-glycoprotein in rat peripheral
lymphocytes (abst) 1786
Schiff base formation, calcitriol receptor function 1539
Schistosomal glomerulopathy, !gA and pathogenesis of ... 920
Scintigraphy in secondary/tertiary hyperparathyroidism
(abst) 1773
Secondary hyperparathyroidism (SHPTH)
Ca-regulated PTH release 1834
gland size and PTH secretion 1663
long-term low Ca dialysis, CAPD (abst) 1434
new analogs of 1,25-(OH)2D3 to blunt (abst) 1429
new scintigraphic method (abst) 1773
parathyroid Vit D receptor, uremia 34
Secreted protein, acidic and rich in cysteine (SPARC)
expression (abst) 1415
Seldinger percutaneous technique, CAPD-catheter
implant (abst) 334
Serotonin concentration in CRF (abst) 710
72-kDa type IV collagenase inhibition, MMP, MC (abst). 1431
Sex hormones, MC proliferation, collagen synthesis 1173
Sickle cell anemia, renal NOS, mice 184
Signaling systems
Ang II, apical Na/H antiport activity, PT 1496
AVP action in SHR mesangium, LDL effect 1506
ET-mediated phospholipid signaling, in rat PT (abst).. 1795
functions of L-selectin (abst) 1783
transduction, cell surface ganglioside, rat podocytes
(abst) 1794
Simvastatin, safety/efficacy in dialysis (abst) 1410
6-mercaptopurine, azathioprine levels, therapeutic
monitoring (abst) 1426
Sjogren's syndrome, renal tubular acidosis (abst) 1403
Skeletal muscle
ATP synthesis, uremia (abst) 1419
PTH effects on bioenergetics (abst) 1405
Skin
capillary permeability, non-diabetic nephropathy (abst). 1771
complications post-transplant, acitretin for (abst) 1396
fibroblasts, premature senescence, IDDM renal disease . 250
passive Arthus reaction, autologous antibody, P-
selectin (abst) 1424
Sleep apnea and ESRD (abst) 1421
Slit diaphragm (filtration slit) and podocyte plasma
membrane 54
SMIT mRNA levels in diabetic rats 1202
Smooth muscle cells
proliferation, lovastatin, PDGF, EGF (abst) 707
proliferation, role of COL4A6 gene alterations (abst). . 1797
VSMC, A.ng II, intracellular effects (abst) 1802
VSMC differentiation, PKC-a mediated by TGF-/3
(abst) 1800
Sodium. See also Na
conductance, stimulation of CFTR inhibits epithelial
(abst) 1811
depletion reduces plasma/renal !P concentrations
(abst) 1404
flux, PT angiotensin receptors, endocytosis 57:S-66
handling, exogenous insulin, renal urate (abst) 330
handling, idiopathic postural hypotension (abst) 1426
intake, subtotal nephrectomy, EGF-AP-1 cascade
(abst) 1799
intracellular, Na reabsorption, CCD (abst) 1795
intracellular, vasopressin regulates in CCD 57:S-57
Na-Ca exchange in renal arterioles 1856, 1889
Na/myo-inositol (SMIT) mRNA, diabetic rats 1202
pump current inhibited by PKC in A6 cell epithelia
(abst) 1796
water resorption, amylin binding in PT, hypertension
(abst) 1392
Sodium bicarbonate, orally, reduces PT injury (abst) . . . . 1807
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Sodium channels
aldosterone-regulated, in A6 kidney cells (abst). . 1783, 1784
amiloride-sensitive conductance, rat PT (abst) 1791
amiloride-sensitive epithelial, in vivo (abst) 1780
mutations in epithelial, pseudohypoaldosteronism type
I (abst) 1795
Sodium transport
AVP-aldosterone synergism, rat CCD (abst) 57:S-35
inhibition by volume expansion, Na/H exchanger,
Na[HCOI3 (abst) 1396
inhibition during chronic volume expansion (abst) 1396
Solute Removal Index (SRI) as dialysis adequacy marker
(abst) 1431
SPARC (secreted protein, acidic and rich in cysteine)
gene expression, rat remnant kidney (abst) 1415
renal interstitial fibrosis, vascular injury 1978
Staphylococcal peritonitis, methicillin-resistant, CAPD
(abst) 696
Staphylococcal phosphatase and GN, rats 290
Steroid pulse therapy, adhesion molecules, platelet-
leukocyte aggregates in MN (abst) 1786
Stones, renal. See Calculi
Stroke predictors in HD patients 1672
Stromelysin, regulation by IL-1/3, rat mesangial cells 894
Sucrose, cell volume control, transplant preservation
fluid (ahst) 1780
Superinduction of peritoneal lL-6 synthesis 1212
Superoxide anion formation, renin secretion in JG cells,
LDL, HDL (abst) 1801
Superoxide dismutase (SOD)
malondialdehyde, CRF, HD (abst) 696
renin expression, acute ischcmic injury (abst) 693
Survival. See Mortality
Sweet's syndrome and pauci-immune crescentic GN
(abst) 1774
Swiss Living Kidney Donor Registry (abst) 1436
Sympatho-vagal balance index in uremia (abst) 1816
Syndrome X, insulin resistance/hyperinsulinemia, renal
disease (abst) 1417
Systemic lupus erythematosus (SLE)
hereditary Clq deficiency, nephritis, IgAN 635
obstructive uropathy with (abst) 705
Systemic vasculitis, alphal-AT deficiency, anti-PR3
antibodies, ANCA (abst) 1395
T
T cells
autoimmune TIN, CD44 expression, cytokines (abst) . . 1787
biased TCR Vy gene usage by infiltrating yb T cells in
IgAN (abst) 1423
CsA regulates adhesion, LFA-1, ICAM-1 45
cytokine mRNA, rejection, sheep (abst) 1409
depletion, crescentic GN (abst) 1413
detection of donor-specific hyporesponsiveness 1019
Hg-induced autoimmune GN (abst) 1818
IL-2R upregulation, costimulation with PrPcspecific
mAb 3F4 (abst) 1426
restricted V/3 repertoire in rejection 2020
role in glomerulonephritis (abst) 1787
THI subset infiltrate kidney, Heymann nephritis (abst). 1423
TH1 type helper, crescent formation in GN (abst) . . . . 1394
Tacrolimus. See FK506 (tacrolimus)
Tamm-Horsfall protein (THP)
anti-GBM GN II as leukocyte mitogen, rat (abst) 1394
anti-THP antibodies, glomerular/interstitial injury
(abst) 1399
carbohydrate content, recurrent stone formers (abst) . . 1433
clearance factor, S fimbriated E. coli (abst) 1809
nephritogenic potential, rat anti-GM GN (abst) 1423
Taurine and cysteinesulfinic acid in uremia 1713
Tendon rupture/tendinitis and fluoroquinolone (abst). . . . 1429
Tertiary hyperparathyroidism, new scintigraphic method
(abst) 1773
Thiazides
-sensitive Na-Cl cotransporter 174
human osteoblast-like cell line MG-63 1476
provoke apoptosis in distal tubule cells 1180
Thick ascending limb (TAL)
Ca2 and Mg2 reabsorption, diet, metabolic alkalosis
(abst) 1789
medullary, plasma membrane vesicles
isolated/characterized 1051
medullary, renal concentrating segments 57:S-154
medullary, urea inhibits cAMP production 26
Thin basement membrane disease
clinical features compared, IgAN (abst) 1416
ocular abnormalities (abst) 1416
3-D analysis of whole mesangium, rat 672
Thrombin stimulates MCP-1 gene transcription, PKC
(abst) 1806
Thrombotic microangiopathy and plasminogen activation. 2011
Thromboxane synthetase inhibitor, CsA nephrotoxicity
(abst) 700
Thyroid function post-transplant, HD (abst) 700
Thyroxine, CsA-induced hyperkalemia, renal Na/K-
ATPase (abst) 701
Tissue inhibitors of metalloproteinases (TIMPs)
in polycystic kidney disease 835
type 1 in experimental nephrosis (abst) 1400
TmDOTP5, as 23Na-NMR spectroscopy shift reagent
(abst) 1405
Torasemide, chronic infusion, ACE inhibition (abst) 1812
Toxicity. See Nephrotoxicity
Trandolapril-verapamil, renal/CV effects, subtotal
nephrectomy (abst) 1807
Transcriptional control by advanced glycation 1166
Transfected CD59 protects mesangial cells 257
Transforming growth factor-a (TGF-p)
allograft expression and CsA toxicity 1634
in chronic renal rejection 489
CREB phosphorylation, activation of CRE in MC with
high glucose 805
CsA nephrotoxicity, role in (abst) 1792
glycine tRNA synthetase, cultured human MC (abst) .. 1398
high glucose, Aug 11, fibronectin, glomerular visceral
EC (abst) 1800
losartan inhibits, hypertensive rats (abst) 489
mediates PKC-a in VSMC differentiation (abst) 1800
in membranous nephropathy 116
prostaglandins and GN 190
Transforming growth factor-f31 (TGF-pl)
cell cycle control by, in glomerular MC (abst) 1816
gene expression, SPARC, rat remnant kidney (abst) . . . 1415
increased mRNA expression, remnant kidney model of
GS (abst) 1400
inhibition of ECM accumulation 148
insulin and Aug 11 in mesangial cells 745
macrophage deactivation by MC 445
matrix proteins, chronic rejection 1904
mRNA expression, HMGCoA reductase inhibition,
diabetic rat glomeruli (abst) 708
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renal overexpression in high glucose, heparin (abst) . . . 1807
synthesis, glucose primes for 1546
Transforming growth factor-f32 (TGF-132)
in compensatory renal hypertrophy (abst) 1406
receptor, mRNA in embryonic rat kidney (abst) 1406
Transplantation. See also Allografts; Donor kidneys
ACEi-related anemia, mechanism of 973
acyclovir for CMV prophylaxis 57:S-62
antibodies to endothelial and EC (abst) 1413
autotransplants for loin pain hematuria, recurrent pain
(abst) 1419
bone edema, acute (abst) 1419
bone mass changes, Vit D receptor genotype 1726
children, 25-year study (abst) 1432
children, cooperative study, Korea (abst) 699
clinical outcome, IgAN and (abst) 698
CMV immunocytochemical assay, peripheral blood
(abst) 711
combined liver-renal, primary type 1 hyperoxaluria
(abst) 1396
cost-utility study, quality of life 235
cyclosporine, nine-year experience (abst) 1395
detection of HCMV DNA in plasma (abst) 1774
dialysis-related amyloid deposits 282
dyslipoproteinemia post-transplant, fluvastatin (abst) . . 1409
effects on thyroid function (abst) 700
failure, CAPD outcome after (abst) 696
flow cytometric analysis, EC, lymphocytes from biopsy
(abst) 1792
fluoroquinolone, tendon rupture, tendinitis (abst) 1429
Gal alpha 1,3 Gal as dominant xenoantigen (abst) . . . . 1413
GI function after (abst) 1420
glomerular PMNs, insertion biopsy (abst) 1409
human CD59, expression by transgenic mice (abst). . . . 1413
humoral alloactivity in 1464
inducible NOS with rejection/infection 2088
living related, mortality (abst) 699
long-term impact, chronic HBV (abst) 1775
misoprostol, renal function, ET-1 (abst) 700
outcome and GN recurrence (abst) 1425
predicting GFR after (abst) 1395
preservation fluid, cell volume control (abst) 1780
PTH, calcitriol, hypercalcemia (abst) 1418
skin complications, acitretin for (abst) 1396
TMP-SMZ prophylaxis (abst) 698
urologic complications (abst) 711
Trimethoprim-sulfamethoxazole (TMP-SMZ)
prophylaxis in transplantation (abst) 698
reversal of antikaliuresis 2063
Trough-to-peak ratio (T/P ratio) assessment, curve
smoothing, BP (abst) 333
Trypsin, tumor associated inhibitor and GFR (abst) 1809
Tubular cells
apoptosis in acute allograft rejection (abst) 1786
cpithelial, aggregates, morphology and integrin
expression (abst) 1786
epithelial, CD44 in MRL-lpr lupus nephritis 156
epithelial, galactose binding protein on EC 754
epithelial, iron and renal tubular cell toxicity 436
epithelial, proliferation with EGF in GN (abst) 1400
furosemide action site, studied by microinjection
technique (abst) 1787
human, fibronectin production, apical protein effect. . . . 760
proteinuria, interstitial scarring (abst) 1782
Tubular dynamics assessed by EBCT 1358
Tubuloglomerular feedback (TGF), chronic ACEi (abst).. 330
Tubulointerstitial injury
albuminuria, integrin expression 1310
RF in rat remnant kidney model (abst) 1401
Tubulointerstitial nephritis (TIN), cytokines promote T
cell-mediated, tubular CD44 (abst) 1787
Tumor associated tiypsin inhibitor and GFR (abst) 1809
Tumor necrosis factor-a (TNFa)
glucose primes for TGF-pl synthesis, human PT cells.. 1546
on human peritoneal mcsothelial cells 219
neutrophil priming mechanisms 407
proinflammatoiy, cytotoxic activity (abst) 1394
T cell-mediated autoimmune TIN, tubular CD44
(abst) 1787
Tungsten, podocyte morphology, PAN (abst) 1400
Tyrosine kinase c-src, MC proliferation (abst) 1784
Tyrosine phosphorylation
EPO signal transduction, endothelial cells 481
Na/K-ATPase a-subunit, insulin activity (abst) 1435
oxidative stress induces 164
U
Ularitide (Urodilatin), renal effects (abst) 1818
Ultrafiltration
CAPD osmotic agents and 56:S-86
coefficient (UFC), peritoneal membrane, transcellular
pores, CAPD (abst) 1771
glomerular, new algorithm for modeling (abst) 1435
high Na dialysate, refilling rate, capillary filtration
coefficient (abst) 1427
Ultrasonography
joint involvement, dialysis-related amyloidosis (abst). . . 1418
prenatal diagnosis, UT anomalies (abst) 706
renal duplex ultrasound diagnoses nephrosclerosis
(abst) 1408
Uninephrectomy, CsA, compensatory renal growth (abst) . 711
U.S. Renal Data System (USRDS)
generated hospitalization tables 571
international comparison, ESRD mortality 1013
Urate, renal, exogenous insulin, Na handling, in health
(abst) 330
Urea
inhibits cAMP production in MTAL 26
rebound and cardiac output 1273
Urea clearance
dialysate proportioner to calculate (abst) 1412
predilution HFD, on-line bicarbonate infusate
production (abst) 1433
serum albumin in CPD 243
Urea kinetic modeling (Kt/V)
assessing adequacy of HD (abst) 1422, 1430
cardiac output and urea rebound 1273
creatinine appearance index, CAPD compliance (abst). 1434
dialysate proportioner to calculate urea clearance
(abst) 1412
increased BFR, HD complications (abst) 695
nutritional status, HD (abst) 694
protein catabolic rate, HD (abst) 1422
quantifying post-dialysis rebound 2094
removal of LMW substances, f32-m, high-flux HD and
HFD (abst) 1434
reproducibility of PD adequacy studies 267
SRI as dialysis adequacy marker (abst) 1431
urea removal quantified, simplified dialysate collection,
HD (abst) 1427
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Uremia
ATP synthesis, skeletal muscle, dialysis (abst) 1419
autonomic cardiovascular control (abst) 1816
gland size and PTH secretion in SHPTH 1663
M-CSF involvement in 1007
melatonin dysregulation in 653
membrane protein damage and methylation 358
parathyroid Vit D receptor 34
ventricular/vascular coupling 600
Ureteric bud cells
activate whole cell Cl conductance, hypotonic stress
(abst) 1791
arborization and nephron deficit 783
Urinaiy AQPI and 2 nephrogenic diabetes insipidus
(abst) 1768
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